
Medicaid cuts push GLP-1 weight-loss drugs out of reach for low-income patients
Massachusetts and several other states have halted or reduced Medicaid coverage for GLP-1 weight-loss medications, leaving low-income patients who started treatment unable to continue. Coverage had been about a third of states in mid-2025, but by 2026 the share fell to roughly one in five, underscoring widening disparities in access to obesity therapies due to high costs.












